It looks like the UK is setting out the red carpet for President Donald Trump and pharma giant GSK seems to be at the forefront of the welcoming committee. Britain’s GlaxoSmithKline on Wednesday became the latest pharmaceutical firm to commit bumper investment into the U.S., as Trump is in the UK for a three-day state visit.
“This week’s State Visit brings together two countries that have led the world in science and healthcare innovation. We are proud to be part of both,” GSK CEO Emma Walmsley said in a statement.
“Today, we are committing to invest at least $30 billion in the United States over the next 5 years, further bolstering the already strong R&D and supply chain we have in the country,” she added.
READ: Trump’s tariffs to empty pharma shelves, industry warns (
The drug maker committed to investing at least $30 billion in U.S. research and developing (R&D) and manufacturing over the coming five years.
GSK plc is a global biopharmaceutical company headquartered in the United Kingdom. It focuses on developing, manufacturing, and marketing innovative medicines and vaccines, with a strong presence in infectious diseases, HIV, respiratory illnesses, and oncology.
The investment includes $1.2 billion toward advanced manufacturing, AI and advanced digital technologies to deliver “next-generation biopharma factories and laboratories in the United States,” the drug maker said.
GSK aims to improve global health through science-led innovation, investing heavily in research and development to bring new treatments to market. The company operates in over 100 countries and collaborates with academic institutions, governments, and other pharmaceutical firms. In recent years.
READ: The $400 Billion Patent Cliff: Big Pharma’s Revenue Crisis (
GSK has undergone significant restructuring, including the demerger of its consumer healthcare business into a separate entity called Haleon. GSK continues to prioritize high-impact pharmaceuticals and vaccines, targeting diseases that pose major public health challenges. The company is also involved in global health initiatives and vaccine access programs, particularly in low- and middle-income countries. GSK trades publicly on the London Stock Exchange and the New York Stock Exchange under the symbol GSK.
The investment commitment comes as President Donald Trump is in the UK for a three-day state visit.
A number of global pharma firms have been ramping up their U.S. investments amid pressure from the Trump administration to bolster U.S. manufacturing and lower domestic drug prices.
By expanding its R&D and manufacturing footprint in the U.S., GSK is not only increasing its capacity to develop cutting-edge medicines but also securing its position in a competitive and fast-changing global market. This move supports its ongoing shift away from consumer healthcare and toward high-impact biopharmaceuticals, signaling a clear focus on innovation-driven growth.